Zevra’s Miplyffa Wins First-Ever US Approval, But In Combination With Off-Label Miglustat

Drug’s List Price Is $1m Per Year On Average

Miplyffa (arimoclomol) was approved for Niemann-Pick disease type C when administered with another high-priced drug used off label as standard of care for about 80% of NPC patients.

Start your own business, launch success rocket or entrepreneur, startup project or boost company growth, invention concept, ambitious businessman entrepreneur push switch to launch rocket into sky. — Zevra will pull the lever on its Miplyffa launch in eight to 12 weeks • Source: Shutterstock

Zevra Therapeutics Inc. received the first-ever US Food and Drug Administration approval in Niemann-Pick disease type C (NPC) for Miplyffa (arimoclomol), but faces some complicating factors: co-administration with an off-label drug, a hefty combined price tag, and a competitor that could be approved imminently.

Miplyffa was cleared on 20 September to treat neurological symptoms associated with NPC in children and adults aged 2 and older in combination with Johnson & Johnson’s Zavesca (miglustat),...

Key Takeaways

Zevra won the first-ever US FDA approval for a drug to treat Niemann-Pick disease type C, Miplyffa (arimoclomol) but in combination with off-label use of Zevesca...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

28 May 2025

• By Kevin Grogan

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

Pipeline Watch: 12 Approvals And 26 Phase III Readouts

26 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

22 May 2025

• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.